The Ledger

475 million dollars: that is what a Zydus Lifesciences subsidiary could pay for a drug that has not finished a single Phase 3 trial, betting on a rare lung disease with no approved treatment anywhere in the United States. Mereo BioPharma and Sentynl Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, announced August 11, 2026 an option and license agreement giving Sentynl U.S. commercial rights and global manufacturing rights to alvelestat, an oral neutrophil elastase inhibitor for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, known as AATD-LD, which affects an estimated 50,000 to 80,000 people in the United States. Mereo will collect a non-refundable option fee now, then, if Sentynl exercises the option, up to 40 million dollars in upfront and research payments plus up to 435 million dollars in regulatory and commercial milestones and double-digit tiered royalties on U.S. sales, for a deal worth up to roughly 475 million dollars before royalties. The companies plan to jointly refine a global Phase 3 trial design, with Mereo retaining rest-of-world rights and leading development; the study could start as early as 2027. Confidence: High. The deal terms and patient-population figures come directly from the companies’ own joint release. Source: Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, GlobeNewswire.

580 million dollars: that is the two year operating loss that sank a 40 year old Minnesota nonprofit insurer, and its court ordered wind down just claimed 102 more jobs. UCare, a Minneapolis nonprofit health plan being liquidated under Minnesota Department of Health oversight after losing 102 million dollars in 2023 and 478 million dollars in 2024, will lay off 102 additional remote employees between October 2 and November 2026 once its state Medicaid contracts formally end October 1, the department confirmed. Nearly 300,000 Medicaid and MNsure enrollees are already transitioning to rival insurer Medica, which acquired UCare’s state contracts, while UCare separately carries roughly 1.1 billion dollars in debt, mostly unpaid bills owed to hospitals, with officials saying not all claims will be paid before 2027. Special deputy commissioner Don Roof said in a statement that “as of October 1, 2026, UCare’s support for the Medicaid contracts will cease, resulting in the layoff of 102 individuals.” Confidence: High on the layoff count, contract end date and the regulator’s own statement; Medium on the cumulative loss and debt figures, which this run found corroborated across multiple outlets citing UCare’s and the state’s own numbers rather than a single primary filing retrieved directly. Sources: Another 102 jobs cut as UCare liquidation continues, InsuranceNewsNet, UCare plans layoff of 100+ remote workers as operations wind down, FOX 9 Minneapolis-St. Paul.

1.4 billion dollars: that is what a real estate investment trust has poured into senior housing and nursing homes so far this year, wagering the sector’s demographic tailwinds are just getting started. American Healthcare REIT reported second quarter 2026 revenue of 674.3 million dollars and net operating income of 137.2 million dollars on August 6, 2026, disclosing it has completed 1.4 billion dollars in new investments since the start of 2026 with more than 800 million dollars of additional deals still in the pipeline expected to close by year end. The company raised full year 2026 guidance to 2.15 to 2.19 dollars in normalized funds from operations per diluted share and 11 to 13 percent same store net operating income growth across its portfolio; chief executive Jeff Hanson said the strategy is to “concentrate capital in senior housing and care, partner with operators who deliver quality outcomes” and lean on the company’s platform to improve asset performance. Confidence: High. The figures come directly from American Healthcare REIT’s own earnings release. Source: American Healthcare REIT Announces Second Quarter 2026 Results, StockTitan.

9,000: that is how many CVS pharmacies will offer 29 dollar online weight loss visits and app based Eli Lilly pricing by this fall, even as Wall Street knocked CVS stock down on questions about what 2027 looks like. CVS Health announced August 5, 2026 a revamped direct to consumer weight management program combining a 29 dollar MinuteClinic virtual visit with no membership fee, same day medication pickup at roughly 9,000 CVS Pharmacy locations, and a new Eli Lilly collaboration that will show transparent, app based cash pricing for Zepbound and Foundayo starting early in the fourth quarter of 2026. The announcement came alongside CVS’s second quarter results, in which adjusted earnings per share rose 42.5 percent to 2.58 dollars and revenue climbed 7.3 percent to 106.1 billion dollars, prompting CVS to raise full year adjusted profit guidance to 7.90 to 8.10 dollars per share from a prior 7.30 to 7.50 dollars; shares nonetheless fell roughly 9 percent as investors focused on management commentary about 2027 headwinds. Confidence: High on the program terms and Q2 figures, which come directly from CVS’s own release and earnings materials; Medium on the stock reaction framing, drawn from market commentary rather than a CVS statement. Source: CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings, CVS Health.

12: that is how many North Carolina dental practices a fast growing dental service organization just agreed to acquire, its fourth state as the private equity backed dental roll up wave keeps rolling. Park Dental Partners announced August 10, 2026 a definitive agreement to acquire Village Family Dental Services Organization, a Fayetteville, North Carolina based multi specialty dental group, adding 12 practice locations and 48 doctors and marking Park’s expansion beyond its existing three state footprint of 222 affiliated doctors across 87 locations. Financial terms were not disclosed; Park chief executive Pete Swenson said the companies share “a commitment to clinical excellence, patient centered care, and long term stewardship,” while Village Family Dental managing partner Dr. Anuj James said joining Park would “accelerate the next chapter of growth” for the practice. Confidence: High. The deal terms come directly from the companies’ own joint release. Source: Park Dental Partners, Inc. Announces Agreement to Acquire Village Family Dental Services Organization, GlobeNewswire.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Alvelestat (AATD-LD) U.S. rights	Sentynl Therapeutics (Zydus Lifesciences subsidiary), from Mereo BioPharma	Rare disease pharma, respiratory	Up to approximately $475 million ($40 million upfront and R&D payments plus up to $435 million in milestones, plus royalties); announced August 11, 2026	Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement, GlobeNewswire
Village Family Dental Services Organization	Park Dental Partners	Dental service organization (DSO)	Undisclosed; announced August 10, 2026	Park Dental Partners Announces Agreement to Acquire Village Family Dental Services Organization, GlobeNewswire

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction review dockets over the last 24 to 48 hours turned up no other new US healthcare transactions beyond the two above.